Pseudomonas aeruginosa is a major bacterial pathogen for which there is rising antibiotic 12 resistance. We evaluated the resistance mechanisms of P. aeruginosa against POL7080, a species- its analogues differ from that of other cAMPs in several key ways. Polymyxins and PG-1 interact with LPS and 30 exhibit broad spectrum anti-microbial activity through self-promoted uptake across the outer membrane, 31 followed by cell lysis through ill-defined mechanisms [11][12][13] . The LptD inhibitors POL7080 and POL7001, 32 however, have been reported to exhibit a non-lytic MOA through LptD inhibition in P. aeruginosa exclusively 6-8 .
. Unfortunately, the discovery of new agents targeting negative bacteria is especially challenging due to the exclusion of most small molecules by their impermeable 22 cell wall 5 and array of efflux pumps. Among the last-resort antibiotics currently used to treat severe multi-drug 23 resistant pseudomonal infections are the polymyxin class of cationic antimicrobial peptides (cAMPs), including 24 polymyxin B and colistin (polymyxin E). More recently, the first-in-class antibiotic POL7080, currently in phase 25 3 clinical trials, was reported with species-specific activity against P. aeruginosa by inhibiting the 26 lipopolysaccharide (LPS) transport protein LptD [6] [7] [8] . The discovery of POL7080 (and its analogue POL7001) 27 emerged from extensive chemical modifications of the cAMP protegrin-1 (PG-1), in which a beta-hairpin was 28 introduced to create cyclized peptidomimetic analogues [9] [10] . The mechanism of action (MOA) of POL7080 and 29 2 its analogues differ from that of other cAMPs in several key ways. Polymyxins and PG-1 interact with LPS and 30 exhibit broad spectrum anti-microbial activity through self-promoted uptake across the outer membrane, 31 followed by cell lysis through ill-defined mechanisms [11] [12] [13] . The LptD inhibitors POL7080 and POL7001,   32 however, have been reported to exhibit a non-lytic MOA through LptD inhibition in P. aeruginosa exclusively 6-8 . 33 To investigate the resistance mechanisms to POL7080 and its analogues, we selected for responsible for adding 4-amino-4-deoxy-l-arabinose (L-Ara4N) to lipid A (Fig. 1A) . The aminotransferase arnB,
69
catalyzing the final step in L-Ara4N addition, was among the most highly upregulated genes in the entire 70 dataset. We confirmed these findings with quantitative reverse transcription PCR (qRT-PCR) after treating 71 mid-log PA14, or resistant PA14-pmrB L172del , with either POL7080 or vehicle control (Fig. 1B) reveal that a signature transcriptional response, the upregulation of key LPS modification genes [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 32 , is 75 constitutively present in the resistant PA14-pmrB L172del based on upregulation of key LPS modification genes.
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These results highlight a common cellular response to LptD inhibitors and polymyxins, and support a shared 77 mechanism by which pmrB mutations confer cross-resistance to POL7080 and colistin.
78
Finally, we investigated whether pmrB resistance mutations mitigate POL7080 binding to the cell 79 surface. We synthesized TAMRA-L27-11 (Fig. S1) , a red-fluorescent analogue of POL7080 with retained 80 inhibitory activity (Fig. S2) , to probe for differential uptake in PA14-pmrB L172del relative to PA14 using confocal 81 microscopy. After treating mid-log PA14 or PA14-pmrB L172del with 500nM TAMRA-L27-11, cells were washed, 82 fixed with 4% paraformaldehyde, and stained with 4′,6-diamidino-2-phenylindole (DAPI) for nucleic acid 83 visualization. Red-field and blue-field confocal microscopy showed comparable DAPI staining but over 3-fold 84 4 reduction in TAMRA-L27-11 uptake in PA14-pmrB L172del relative to PA14 (Fig. 2) 
